GlaxoSmithKline: advance purchase agreement with US Pentagon
(CercleFinance.com) - GlaxoSmithKline has entered into an advance purchase agreement with the US military for the supply of sotrovimab, the experimental treatment against Covid-19 that it is currently developing with Vir Biotechnology.
In a notice published on its website, the Pentagon specifies that its order for this treatment, composed of monoclonal antibodies, is worth nearly 280 million dollars.
The Department of Defense says that the treatment will be manufactured by GSK at its site in Durham (North Carolina).
Sotrovimab, which has not yet been approved by health authorities, can be used to treat patients with mild symptoms of Covid who do not require additional oxygen, although who are at high risk of developing a severe form of the disease.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
In a notice published on its website, the Pentagon specifies that its order for this treatment, composed of monoclonal antibodies, is worth nearly 280 million dollars.
The Department of Defense says that the treatment will be manufactured by GSK at its site in Durham (North Carolina).
Sotrovimab, which has not yet been approved by health authorities, can be used to treat patients with mild symptoms of Covid who do not require additional oxygen, although who are at high risk of developing a severe form of the disease.
Copyright (c) 2021 CercleFinance.com. All rights reserved.